For more than 20 years Thomas has served as CFO of several European and US biotech companies, where he directed growth and financial strategies with particular emphasis on transatlantic company building and outreach to US capital markets. In his last CFO position at Origenis GmbH / IZB Martinsried, he focused on the commercialization of its IP portfolio by the foundation of US-based Neuron23, Inc. dedicated to precision medicines for neurodegenerative diseases. Since its launch in 2019, the company has raised a total of $213.5 million from Kleiner Perkins, Westlake Village BioPartners, Perceptive Advisors, Softbank Vision Fund 2 and other high-profile VC and cross-over funds.

Prior to Origenis, Thomas directed the financing strategy of ESBATech AG / Zurich, that positioned the company as a leader in its field and attracted a syndicate of top quartile US and European investors (Clarus Ventures, SV Health Investors, HBM Partners, Novartis Venture Fund). ESBATech, now a Novartis company, was recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications by the trade sale of its ophthalmology franchise to Alcon, Inc. for $ 589 million in 2009. The most advanced product from the ESBATech platform received market approval by the FDA in October 2019 and shortly thereafter in all major markets.
Thomas´ track record is complemented by numerous transactions (in-/out-licencing, M&A deals and IPOs) that created both equity value and attractive ROIs for investors.

Thomas studied economics and served as an Assistant Lecturer at Ludwig-Maximilian-University (LMU) of Munich, before he started his business life in US investment banking. He further graduated from the Advanced Management Program of Harvard Business School (AMP 166) and is since 2004 a member of Harvard Alumni Association.